Clinical Trial
doi: 10.1016/0030-4220(83)90096-8.
Effect of Sialor in treatment of xerostomia in Sjögren's syndrome
- PMID: 6358997
- DOI: 10.1016/0030-4220(83)90096-8
Item in Clipboard
Clinical Trial
Effect of Sialor in treatment of xerostomia in Sjögren's syndrome
Oral Surg Oral Med Oral Pathol.
1983 Nov.
Abstract
Sialor, a sialogogue, was studied in a double-blind crossover trial in patients with autoimmune exocrinopathy (Sjögren's syndrome). Sialor appears to frequently alleviate the symptoms of xerostomia and increase salivary flow rate, and it is rarely associated with side effects. Sialor is useful in management of xerostomia in patients with Sjögren's syndrome and may also be of value in the treatment of xerophthalmia.
Similar articles
-
Clinical trials of a sialogogue in humans: a preliminary report.Spec Care Dentist. 1982 Jan-Feb;2(1):17-9. doi: 10.1111/j.1754-4505.1982.tb00027.x. Spec Care Dentist. 1982. PMID: 6951304 No abstract available.
-
Effect of Saliment on parotid salivary gland secretion and on xerostomia caused by Sjögren's syndrome.Scand J Dent Res. 1982 Apr;90(2):157-62. Scand J Dent Res. 1982. PMID: 7041242 Clinical Trial.
-
Treatment of xerostomia in patients with primary Sjögren's syndrome with sulfarlem.Scand J Rheumatol Suppl. 1986;61:250-2. Scand J Rheumatol Suppl. 1986. PMID: 3473639
-
[Sjögren's syndrome in the elderly].Ann Med Interne (Paris). 2002 Oct;153(6):378-82. Ann Med Interne (Paris). 2002. PMID: 12486386 Review. French.
-
Sjogren's syndrome: oral and dental considerations.J Am Dent Assoc. 1993 Mar;124(3):74-6, 78-82, 84-6. doi: 10.14219/jada.archive.1993.0064. J Am Dent Assoc. 1993. PMID: 8335784 Review.
Cited by
-
Targeting NRF2 signaling for cancer chemoprevention.Toxicol Appl Pharmacol. 2010 Apr 1;244(1):66-76. doi: 10.1016/j.taap.2009.08.028. Epub 2009 Sep 2. Toxicol Appl Pharmacol. 2010. PMID: 19732782 Free PMC article. Review.
-
Anethole Dithiolethione Increases Glutathione in Kidney by Inhibiting γ-Glutamyltranspeptidase: Biochemical Interpretation and Pharmacological Consequences.Oxid Med Cell Longev. 2020 Sep 28;2020:3562972. doi: 10.1155/2020/3562972. eCollection 2020. Oxid Med Cell Longev. 2020. PMID: 33062138 Free PMC article.
-
Salivary Secretory Disorders, Inducing Drugs, and Clinical Management.Int J Med Sci. 2015 Sep 22;12(10):811-24. doi: 10.7150/ijms.12912. eCollection 2015. Int J Med Sci. 2015. PMID: 26516310 Free PMC article. Review.
-
Dithiolethiones for cancer chemoprevention: where do we stand?Mol Cancer Ther. 2008 Nov;7(11):3470-9. doi: 10.1158/1535-7163.MCT-08-0625. Mol Cancer Ther. 2008. PMID: 19001432 Free PMC article. Review.
-
Treatment of oral dryness related complaints (xerostomia) in Sjögren's syndrome.Ann Rheum Dis. 1999 Aug;58(8):465-74. doi: 10.1136/ard.58.8.465. Ann Rheum Dis. 1999. PMID: 10419864 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical